Skip to main content
. Author manuscript; available in PMC: 2018 Feb 1.
Published in final edited form as: J Vasc Interv Radiol. 2016 Dec 9;28(2):231–237.e2. doi: 10.1016/j.jvir.2016.09.022

Figure 2.

Figure 2

Overall survival analysis of Medicare HCC patients, dichotomized based upon whether or not they were treated with TACE, irrespective of other non-TACE treatments. Survival was significantly improved in patients treated with TACE compared to those not treated with TACE (median survival: 20.1 months-TACE vs. 4.3 months-no TACE, p<0.0001).